Professional Documents
Culture Documents
Grand Round Presentation Edited HX and Exam
Grand Round Presentation Edited HX and Exam
Grand Round Presentation Edited HX and Exam
PRESENTATION
PRESENTERS:
DR. EFFESO KAGUO
DR. SHANEABBAS MOHAMED
DR. AHLAM MATTAR
• Weakness was persistent ,with no periods of remission or exacerbation over course of the
day
• Four months after onset of symptoms the patient couldn’t be able to walk even with
support
• Gradual on onset
• Started as blurring of vision on the left eye and later on involved both
eyes within 2 days
• Progressed to complete visual loss within one week
• It was associated with frontal headache, eye pain described as dull
aching within the eyes worsened by eye movement
• No eye discharge or tearing, redness or itching
Course of Illness
• At onset of symptoms patient (Rt upper and lowerlimb weakness)
attended at MRRH and was referred to MNH
• Was admitted for two days and was discharged with a diagnosis of
stroke. No imaging was done.Discharged with atorvastatin 20mg od and
Nat B
• CN V:
• Can clench teeth, normal facial sensation (V1,V2,V3)
• CN VII:
• Can Close Eyes Against Resistance, Symmetrical Face
Cranial Nerves
• CN VIII:
• Can Hear
• CN IX, X:
• No Uvula Deviation and gag reflex present
• CN XI:
• Can Raise Shoulders against resistance
• CN XII:
• Can Protrude tongue, no fasciculation or atrophy Of the tongue
FASCULATIONS NO NO
FASCICULATIONS NO NO
Differential diagnosis
• Multiple Sclerosis
• Myelin Oligodendrocyte Glycoprotein Antibody - Associated
Disease (MOGAD)
NMOSD
POSTIVE NEGATIVE
POSTIVE NEGATIVES
• Optic involvement • No features of cortical or brain
• UMN signs stem involvement
INVESTIGATIONS
Total spine MRI
Brain MRI
CSF analysis
Visual Evoked Potential
Thyroid Function Tests
TEST RESULT REFERENCE
RANGE
TSH 0.6094 0.49 – 4.67
Serum ADA 10
Serum Electrolytes and Renal Function test
TEST RESULTS
Potassium 4.5
Chloride 101
eGFR 117ml/min/1.73m2
Sodium- 138 RBG- 5.3mmol/l
Potassium- 4.17 HBA1C 5.8%
Calcium- 2.11 (1.9-
T3-2.16 (1.4- )
T4- 1.1 (0.7- )
TSH- 0.6 (0.4- )
Creatinine 66 (50- 120mmol/L)
BUN- 3.2 mmol/L (2.1-8.5)
Creatinine kinase 150 (55-190u/l)
AST-
ALT
Autoimmune markers
MARKER RESULT
ANA NEGATIVE
ANCA C NEGATIVE
ANCA P NEGATIVE
• NORMAL FBC
Serology
HIV NEGATIVE
VDRL NEGATIVE
HBsAg NEGATIVE
HepCAb NEGATIVE
URINALYSIS
• Dipstick Microscopy
Colour- normal White blood cell- negative
Ph- 6.7 Red blood cells- negative
Specific gravity- 1.02
Epithelia cells- negative
Glucose- negative
Ketone- negative
Protein- negative Conclusion- Normal urinalysis
Urobilinogen-negative
Leucocytes- negative
Nitrite- negative
WISH LIST
• Aquaporin-4 (AQP4-IgG) antibodies test
International consensus diagnostic Criteria for NMO
1. Criteria for NMOSD with AQP4-IgG
• One or more of the six core clinical characteristics
• Positive serum test for AQP4-IgG with the use of the best available detection
method (cell-based assay strongly recommended)
• No alternative diagnoses
2. Criteria for NMOSD without AQP4-IgG or with unknown antibody status
• Two or more of the six core clinical characteristics; must include at least
one of the following three core clinical characteristics:
• Acute optic neuritis with either no abnormalities or only nonspecific white-
matter lesions in the brain on MRI, or with orbital MRI showing a lesion
extending over more than half the optic-nerve length or involving the optic
chiasm
• Acute myelitis with a longitudinally extensive cord lesion on MRI
• Area postrema syndrome with a dorsal medullary lesion on MRI
• Negative test (or tests) for AQP4-IgG
Final diagnosis
• NEUROMYELITIS OPTICA
DISCUSSION
NMO (neuromyelitis optica)
Management of the patient
Progress
Why this case
• Rare case
• Stroke in young adult without risk factors?? - need thorough
evaluation!
• Diagnostic challenges
Acknowledgement
• Dr. Kimambo - Neurophyscian
• Dr.Mohamed Manji
• Dr. Brighton
• Dr. Zuwena- Radiologist (MNH - Mloganzila)
• Dr. Hyera
• Fellow residents